Medullary Thyroid Cancer Market Size, Share, Research Report 2030 | DelveInsight

Medullary thyroid carcinoma (MTC) arises from the calcitonin (CT)-producing parafollicular C cells of the thyroid. In mammals, C cells migrate from the neural crest to the thyroid gland, along with the ultimobranchial body. They are located in the basal layer of thyroid follicles and account for about 1% of thyroid cells.

DelveInsight's "Medullary Thyroid Cancer Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Medullary Thyroid Cancer, historical and forecasted epidemiology as well as the Medullary Thyroid Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Click here to read more on Medullary Thyroid Cancer.

Medullary Thyroid Cancer Disease Overview

MTC is usually firm in consistency, either whitish or red in color, and well-demarcated or grossly invasive on the cross-section. At histological examination, classic MTC consists of sheets of spindle-shaped, round or polygonal cells separated by fibrous stroma, forming a nested pattern characteristic of endocrine tumors. The nuclei are usually uniform in shape with rare mitotic figures. The cytoplasm is eosinophilic with a fine granular appearance. In addition, amyloid deposits are also observed between tumor cells in 60–80% of tumors.

The tumor metastasizes early to both para-tracheal and lateral cervical lymph nodes; lymph node metastases are found in 20–30% of patients with MTC <1 cm in diameter (T1), 50% of patients with a T2 tumor, and up to 90% of patients operated on for T3-4 tumors. Metastases outside the neck may occur in the liver, lungs, bones, and less frequently, brain and skin.

The DelveInsight Medullary Thyroid Cancer market report gives a thorough understanding of the Medullary Thyroid Cancer by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 

Request for a free sample copy of the report: https://www.delveinsight.com/sample-request/medullary-thyroid-cancer-market

Medullary Thyroid Cancer Epidemiology  

Thyroid cancer is the most common malignancy of the endocrine system and accounts for approximately 2% of all new cancer diagnoses. MTC is the third most common thyroid malignancy after papillary and follicular thyroid carcinoma. About 98% of patients with MEN 2 have germline mutations in exons 5, 8, 10, 11, 13, 14, 15, or 16 of the RET gene. De novo mutations have been found in 4–10% of index cases with MEN 2A and FMTC, and are located on the allele inherited from the patient’s father. Rare patients with MEN 2B phenotype have double RET mutations.

Medullary thyroid carcinoma (MTC) accounts for 5–8% of all thyroid cancers.

There are two distinct hereditary types of MTC, and each variant of MEN2 results from different RET gene mutations, with good genotype/phenotype correlation.

The Medullary Thyroid Cancer epidemiology division provide insights about historical and current Medullary Thyroid Cancer patient pool and forecasted trend for every seven major countries.

Key Findings

1.    MTC has both sporadic and hereditary/familial forms. The majority of MTC patients have sporadic MTC (75 %), while 25 % suffer from hereditary MTC.

2.    The sex ratio in sporadic MTC is 1:1.3 (male: female), showing a slight female predominance, while familial cases have no sex predilection due to their autosomal dominant inheritance pattern.

3.    Estimated prevalence in the general population is 1/14,300. Ten-year survival is about 80% when patients are not surgically cured and reaches 95% when the biological marker CT is normalized after surgery.

Medullary Thyroid Cancer Key Pharma Players Involved

1.    Globeimmune

2.    Blueprint Medicines

3.    Turning Point Therapeutics Inc.

Get a free report on Medullary Thyroid Cancer @ https://www.delveinsight.com/sample-request/medullary-thyroid-cancer-market

Medullary Thyroid Cancer Market Outlook

Medullary thyroid cancer is a form of thyroid carcinoma that originates from the parafollicular cells (C cells), producing the hormone calcitonin. Approximately 25% of medullary thyroid cancer cases are genetic in nature, caused by a mutation in the RET proto-oncogene.

Diagnosis is primarily performed via fine-needle aspiration of the thyroid lesion to distinguish it from other types of thyroid lesions. Microscopic examination will show an amyloid stroma with hyperplasia of parafollicular cells. Surgery and radiation therapy have been the major treatments for medullary thyroid carcinoma.

Current Major Treatment Options:

1.    Radiation

2.    Cabozantinib

3.    Surgery

4.    Vandetanib

The Medullary Thyroid Cancer market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Medullary Thyroid Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

According to DelveInsight, Medullary Thyroid Cancer market in 7MM is expected to change in the study period 2017-2030.

Key Findings

1.    The market size of medullary thyroid cancer (MTC) is anticipated to increase during for the study period, 2017–2030.

2.    The increase in market size is a direct consequence of the increasing incident population of medullary thyroid cancer patients in the 7MM.

Visit our free repository of reports @ https://www.delveinsight.com/report-store.php

Comments

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more